Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $2.01, $0.85 better than the analyst estimate of $1.16. Revenue for the quarter came in at $649.7 million versus the consensus estimate of $628.18 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.